Navigation Links
A molecular switch is linked to a common breast cancer
Date:11/8/2007

Researchers have discovered that a molecular switch in the protein making machinery of cells is linked to one of the most common forms of lethal breast cancer worldwide. The discovery by researchers at NYU School of Medicine could lead to new therapies for the cancer, called locally advanced breast cancer (LABC).

Although precise data isnt available, LABC may account for 50 percent or more of breast cancers among women in developing countries, and 30 percent of breast cancers among socially disadvantaged and minority women in the United States. This type of cancer is defined by a large tumor that is about 2 inches or larger in diameter, about the size of a plum, when first diagnosed. The cancer may have spread into surrounding lymph nodes or other tissues. However, it hasnt yet spread to more distant areas in the body.

Without treatment, fewer than 20 percent of patients with LABC are living five years after their diagnosis. Unfortunately, even with appropriate treatments, this cancer is deadlier than other types of breast cancer that are detected earlier.

With funding from the Breast Cancer Research Foundation and the Department of Defense, Robert J. Schneider, Ph.D., the Albert B. Sabin Professor of Molecular Pathogenesis, and Silvia C. Formenti, M.D., the Sandra and Edward H. Meyer Professor of Radiation Oncology and Chairwoman of Radiation Oncology, and their colleagues at NYU School of Medicine have made LABC the focus of a coordinated effort to understand the disease.

This disease has not been sufficiently studied, in part because of the social, psychological, economic, and cultural barriers that may stand in the way of obtaining care, says Dr. Formenti.

Our study shows that an unusual molecular switch occurs that is essential for the development of these large tumors. We think that this switch could be a target for new therapies, says Dr. Schneider.

The new study is published in the November 9, 2007 issue of the journal Molecular Cell.

Drs. Schneider and Formenti led the new study which found that two molecules were unusually abundant or overexpressed specifically in locally advanced breast cancers. Further analysis in mice revealed that the molecules orchestrated a switch in the use of messenger RNA, a kind of ferry service that carries information for making proteins. This switch, the researchers found, occurs when tumors become starved for oxygen, a condition known as hypoxia. The switch permits the selective expression of proteins that are required for tumors to carry out angiogenesis, the process of developing a blood supply. It also enables tumors to grow to a large size and to progress.

The identification of the molecular switch and its importance for development of locally advanced breast cancer reveals realistic targets for the development of new therapeutics to block tumor angiogenesis and progression in breast and possibly other cancers, says Dr. Schneider.


'/>"/>

Contact: Pamela McDonnell
Pamela.McDonnell@nyumc.org
212-404-3555
New York University Medical Center and School of Medicine  
Source:Eurekalert

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A molecular switch is linked to a common breast cancer
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: